Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $19.60 Analyst target: $37.00 Upside: 88.78%
Seaport Therapeutics, Inc. (SPTX) is a pioneering biopharmaceutical firm dedicated to advancing cutting-edge immune-oncology therapies to meet critical unmet medical needs, particularly in the field of oncology. The company leverages innovative technologies and a robust research pipeline to develop targeted treatment solutions for complex diseases, with a strong focus on cancer. Supported by strategic collaborations and an experienced management team, Seaport Therapeutics is well-positioned to drive scientific advancements that enhance patient outcomes and reshape the landscape of cancer treatment and immunotherapy.
See the full interactive analysis & chart →Informational only — not investment advice.